Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein
© The Author(s). 2016
Received: 25 May 2016
Accepted: 26 November 2016
Published: 1 December 2016
Key features of advanced ovarian cancer include metastasis via cell clusters in the abdominal cavity and increased chemoresistance. Resveratrol and derivatives of resveratrol have been shown to have antitumour properties. The purpose of this study was to investigate the effect of resveratrol and acetyl-resveratrol on 3D cell aggregates of ovarian cancer, and establish if NF-κB signalling may be a potential target.
Poly-HEMA coated wells were used to produce 3D aggregates of two ovarian cancer cell lines, SKOV-3 and OVCAR-5. The aggregates were exposed to 10, 20 or 30 μM resveratrol or acetyl-resveratrol for 2, 4 or 6 days. Cell growth and metabolism were measured then ELISA, western blot and immunofluorescence were utilised to evaluate VEGF, IL-8 and NF-κB levels.
Resveratrol and acetyl-resveratrol reduced cell growth and metabolism of SKOV-3 aggregates in a dose- and time-dependent manner. After 6 days all three doses of both compounds inhibited cell growth. This growth inhibition correlated with the attenuated secretion of VEGF and a decrease of NF-κB protein levels. Conversely, the secretion of IL-8 increased with treatment. The effects of the compounds were limited in OVCAR-5 cell clusters.
The results suggest that resveratrol and its derivative acetyl-resveratrol may inhibit in vitro 3D cell growth of certain subtypes of ovarian cancer, and growth restriction may be associated with the secretion of VEGF under the control of the NF-κB protein.
KeywordsOvarian cancer Resveratrol Acetyl-resveratrol VEGF NF-κB Cell clusters IL-8
Ovarian cancer is a lethal gynaecological cancer and is the seventh most common cause of cancer death among women . The majority of women present with an advanced stage of the disease . The current treatment options of debulking surgery and chemotherapy are generally not curative in advanced stages of the disease due to recurrence and chemoresistance . Therefore, alternative treatments that target cancer cells, reduce tumour growth and increase tumour-free survival are of great importance.
Ovarian cancer metastasises via the fluid in the peritoneal cavity. Cells slough off the primary tumour and form small 3D clusters or aggregates in the peritoneal fluid. The accumulation of peritoneal fluid, which is known as ascites, is often associated with advanced ovarian cancer and correlates with poor prognosis . The microenvironment of the ascitic fluid is rich in a wide range of growth factors and cytokines, and these are believed to sustain cell cluster survival, growth and secondary site establishment . Relatively little is known, however, about the interactions between ascitic fluid components and the 3D aggregates. The 3D aggregates of ovarian cancer cells are integral to metastasis, and are possibly involved with the development of chemoresistance . Few studies have investigated the use of potential therapeutic agents against the 3D aggregates of ovarian cancer.
Our knowledge of ovarian cancer aggregate survival in ascitic fluid is limited. However, studies on other types of solid tumour, coupled with analyses of pertinent proteins suggest that angiogenic and inflammatory mediators may play a significant role. Of the numerous pro-angiogenic cytokines vascular endothelial growth factor (VEGF) is one of the most well described. In addition to being a key regulator of angiogenesis, it also enhances cell survival, proliferation and migration [7, 8]. Studies have revealed that VEGF is over expressed by ovarian cancer [9, 10]. Interleukin-8 (IL-8) is another regulation protein involved in tumorigenic activities in cancers, and has been reported to be over expressed in ovarian cancer [11–13], suggesting its importance to ovarian cancer carcinogenesis.
There is evidence that VEGF and IL-8 expression in ovarian cancer are under the transcriptional control of nuclear factor kappaB (NF-κB) . The NF-κB family of transcription factors are activated via two signalling pathways . In normal cells, NF-κB activation is very tightly regulated, but constitutive activation has been identified in a range of cancers [16–18] suggesting that NF-κB signalling may be important in cancer survival. Furthermore, in some cancer types the activation of NF-κB correlates with the expression of VEGF  and IL8 . However, this correlation is not well understood in ovarian cancer.
The polyphenol resveratrol is a possible inhibitor of the NF-κB signalling pathway in ovarian cancer. Resveratrol is one of the major antioxidants found in the skin of red grapes and has anti-inflammatory , cardioprotective  and anti-carcinogenic properties . It has been linked to the inhibition of NF-κB in prostate  and lung cancer , and the down regulation of VEGF  and IL-8 . However, there have been no reports on the effects of resveratrol on NF-κB activity, cytokine expression or their correlation with the growth of ovarian cancer clusters.
Although resveratrol appears to be a very promising cancer treatment, it has low bioavailability [28, 29], because of this the resveratrol derivative acetyl-resveratrol has aroused interest. In chemopreventive and chemotherapeutic studies, it appears to possess the same characteristics as resveratrol, but may not undergo such rapid metabolism in the liver and with increased cellular uptake may have greater bioavailability . The hydroxyl groups of resveratrol are acetylated in acetyl-resveratrol which accounts for it being a more stable compound and increased uptake in the body .
In the present study, we examined the effect of resveratrol and acetyl-resveratrol on cell growth and on the production of regulatory factors in 3D aggregates of two ovarian cancer cell lines. Our data shows that both compounds significantly inhibit cell growth, VEGF secretion and NF-κB activation in a time-, dose- and cell line dependent manner. The secretion of IL-8 increased.
The human ovarian adenocarcinoma cell lines SKOV-3 and OVCAR-5 were obtained from Dr. Judith McKenzie, Haematology Research group, University of Otago, Christchurch, New Zealand. Both cell lines were maintained in Dulbecco’s Modified Eagle Medium (GIBCO®, Life Technologies, New Zealand), supplemented with 10% fetal bovine serum (GIBCO®, Life Technologies, New Zealand), PenStrep (GIBCO®, Life Technologies, New Zealand) at a working concentration of 100 units/ml penicillin and 100 μg/ml streptomycin, 2 mM GlutaMAX™ (GIBCO®, Life Technologies, New Zealand) and 2 μg/ml Fungizone® (Life Technologies, New Zealand). The supplemented media is henceforth referred to as working media. SKOV-3 and OVCAR-5 cells in working media were continuously maintained in a culture flask at 37 °C in a humidified 5% CO2 atmosphere incubator.
Production of 3D aggregates
To prevent adhesion of cells to culture plates, 12-well culture plates were pre-coated with 24 mg/ml Polyhydroxyethylmethacrylate (poly-HEMA) (Sigma, New Zealand) prior to cell culturing (0.5 ml/well). Prior to coating, poly-HEMA was fully dissolved in 95% ethanol at a concentration of 24 mg/ml and was heated to approximately 70 °C. After the poly-HEMA was placed in the wells the plates were left overnight at 37 °C on an orbital shaker. Prior to cell culture, the coated wells were washed once with PBS at pH 7.4. To detach the cell monolayer of the SKOV-3 and OVCAR-5 cell lines from the flask surface, they were incubated with 1x trypsin-EDTA for 20–30 min. Cells were counted with a haemocytometer to determine the concentration of the cells in suspension. Cells were then plated at a density of 200,000 cells/well and were incubated at 37 °C in a humidified 5% CO2 atmosphere for 6 days. Over this time the cells became clusters and aggregates. Working media was refreshed every 2 days with 1 ml of fresh working media.
Treatment with resveratrol, acetyl-resveratrol and Bay 11-7085
Resveratrol and acetyl-resveratrol were provided by Dr. Saurabh Shah, Biotivia (USA). A NF-κB inhibitor, Bay 11-7085, was purchased Sigma-Aldrich (Auckland, New Zealand). Resveratrol was dissolved in a 50:50 combination of PBS and DMSO, acetyl-resveratrol and Bay 11-7085 were dissolved in 100% DMSO. Fresh working media containing the relevant compounds (at concentrations of 10, 20 and 30 μM) was replaced every 2 days for up to 6 days. Thus, at the endpoint of culturing the cells had a total incubation time of 8, 10 or 12 days respectively; 6 days developing the aggregates and 2, 4 or 6 days of treatment. For all experiments, the final concentration of DMSO used in controls was the concentration of DMSO that was present in the 30 μM treatments. At least 4 independent experiments were carried out for each treatment and within each experiment there were 3 replicates.
Growth determination using the crystal violet assay
Growth of the 3D aggregates was quantified indirectly using crystal violet staining. In brief, cell aggregates were isolated and incubated with 1x trypsin-EDTA for 20 min at 37 °C. Cells were washed twice with PBS (pH 7.4) and were incubated for a further 15 min at 37 °C with 2 mg/ml crystal violet in 2% (v/v) ethanol in milliQ water. The cells were then washed with milliQ water to remove unbound crystal violet, and were isolated by centrifugation at 1500 rpm for 5 min. The supernatant was removed and the process repeated 3 times until the supernatant was colourless. Cells were then lysed in 10% (w/v) sodium dodecyl sulphate (SDS) solution. 200μl of the homogenous cell lysate was then loaded onto a 96-well plate. The optical density was determined at 560 nm (OD560) using a microplate reader (SpectraMax M5, Molecular Devices).
Cellular metabolism determination using the Alamar blue assay
On the 6th day of treatment with compounds, 0.5 ml media was removed from each well and 50 μl of Alamar blue dye (ThermoFisher Scientific, New Zealand) added to cell aggregates. Aggregates were incubated at 37 °C with the dye for 4 h after which 200 μl of media from each well was transferred to a 96-well plate. The absorbance at 570 and 600 nm was measured using a microplate reader (SpectraMax M5, Molecular Devices). Cellular metabolism was calculated from the difference of absorbance at 600 and 570 nm.
Detection of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8)
The conditioned media of the control and treated cells (2, 4 or 6 days) was used to determine secreted VEGF and IL-8 levels. The conditioned media were centrifuged at 1500 rpm to remove cell debris and stored at -80 °C until assayed using the DuoSet Human VEGF ELISA kit (R&D System, New Zealand) and the DuoSet Human IL-8 ELISA kit (R&D System, New Zealand). The assays were carried out according to the manufacturer’s instructions. Samples were diluted 50%, the amount of VEGF or IL-8 was determined by comparing absorbance of each well to a standard curve and corrected for total protein.
Cell aggregates were harvested after their respective treatments by centrifugation at 1500 rpm for 5 min and the cell pellet was resuspended in cold RIPA buffer containing protease inhibitor cocktail tablets (Complete Mini, Roche, New Zealand). The cell lysates were left on ice for 30 min to ensure total cell lysis. Total protein was determined using a Pierce™ BCA protein assay kit (ThermoFisher Scientific, New Zealand) according to the manufacturer’s instructions. Sample buffer (0.2% (v/v) bromophenol blue, 25% (v/v) glycerol, 10% SDS in Tris-HCl and pH 6.8) was added and protein lysates were boiled for 10 min. Samples (10 μg protein) were fractionated in 5–12% SDS-PAGE gels and transferred to PDVF membranes (Bio-Rad Laboratories, Hercules, USA). The markers used were MagicMark Western Protein Standard (Thermofisher, New Zealand) and Precision Plus Protein Standard (Bio-Rad, Hercules, New Zealand). The membranes were blocked for 60 min with either 5% (w/v) nonfat skim milk (Pams brand, New World, New Zealand) or 1% (w/v) bovine serum albumin (ThermoFisher Scientific, New Zealand) in 1% tween-TBS. Antibodies were diluted to 1/500 to 1/1000 with the appropriate blocking solution, and membranes were incubated with primary antibodies overnight at 4 °C. Membranes were developed using either donkey anti-mouse IgG-AP or goat anti-rabbit IgG-AP secondary antibodies (Santa Cruz, CA, USA, 1:10,000). Antibody localisation was determined using a chemiluminescent detection kit (Amersham ECL Prime Western Blotting Detection Reagent Kit, GE Healthcare) and the bands visualized using Alliance 4.7, Unitec (Cambridge, UK). The primary antibodies used were PCNA (sc-25280), pIκBα (sc-8404), NF-κB (sc-372), pNF-κB (sc-33020) and GAPDH (sc-25778), all purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Cell aggregates were harvested after treatments, they were then centrifuged and the supernatant removed. 1 ml of ice cold mixture of methanol:acetone (50:50% (vol/vol)) solution was added to the OVCAR-5 and SKOV-3 cell aggregates and the samples were stored at −20 °C until analysis. Prior to sectioning, SKOV-3 aggregates were stained with the aniline blue dye solution (1% in water (Sigma-Aldrich LTD, New Zealand)) for 20 min and washed with PBS twice. The stained SKOV-3 aggregates were then imbedded in CryO-Z-T solution (Ted Pella Inc., USA) and frozen overnight at -80 °C. SKOV-3 samples were then sectioned into 7 μM thick slices, two slices were placed on appropriately labelled Superfrost plus slides (Menzel-glaser, Germany), 6 slices per sample were collected, and stored at -20 °C until analysis.
The OVCAR-5 cell clusters were removed from the methanol/acetone solution, washed with PBS pH 7.4 and placed onto slides. Slides of both cell lines were dried and blocking buffer added for 1 h at room temperature. Primary antibodies to detect NF-κB or pNF-κB proteins were diluted to 1:200 in 2% BSA in PBS, added to the slides and the slides were incubated overnight at 4 °C. The secondary antibody goat anti-rabbit IgG conjugated with Atto 594 nm (Sigma-Aldrich LTD, New Zealand, 1:1000) was added to slides which were then incubated for 1 h at 37 °C, and then samples were stained with 10 μg/ml Hoechst (Invitrogen, New Zealand) for 20 min. The slides were washed extensively with PBS + 0.1% Tween-20, pH 7.4. Cells were observed and imaged with an epifluorescence microscope (AxioVision 4.5. Apotome software, Carl Zeiss, Oberkochen, Germany).
At least four independent experiments were carried out for each treatment and these were statistically analyzed using GraphPad Prism software (La Jolla, CA, USA). p < 0.05 was considered to indicate statistical significance determined by one way ANOVA. All data are presented as mean ± SEM.
Attenuation of cellular growth and metabolism by resveratrol and acetyl-resveratrol
Attenuation of Vascular Endothelial Growth Factor (VEGF) production by resveratrol and acetyl-resveratrol
Resveratrol and Acetyl-resveratrol increase the secretion of Interleukin-8 (IL-8)
Effects of resveratrol and acetyl-resveratrol on the expression and activation of NF-κB protein
Attenuation of cell growth and VEGF secretion by a NF-κB inhibitor
Of all the gynaecological cancers ovarian cancer is the deadliest. It is very difficult to detect, therefore, three quarters of patients upon diagnosis already have an advanced stage of the disease. The current treatment options for this cancer usually become ineffective after a while and overall survival rates are not good. Finding alternative treatments and targets related to chemoresistance is of the utmost importance.
Advanced ovarian cancer disseminates via cells in ascitic fluid, in which the cells survive by aggregating together . These aggregates then settle at a secondary location and grow into tumours. The morphology of metastasising ovarian cancer cells has been implicated in the development of chemoresistance . Targeting aggregates that are formed by these cells, therefore, could be very useful in the treatment of ovarian cancer. In this study, we grew 3D aggregates of the SKOV-3 and OVCAR-5 cell lines and demonstrate that resveratrol and acetyl-resveratrol are capable of restricting the growth and metabolism of the SKOV-3 aggregates in a time- and dose-dependent manner. We used a 10 μM dose as this concentration can be found in food products and is pharmacologically relevant . Previously we have tested 5, 10, 50 and 100 μM resveratrol and acetyl resveratrol  and found that 50 and 100 μM of both compounds was able to reduce cell growth and increase cleaved PARP protein. Therefore, we chose to investigate 20 μM and 30 μM as they are in between the pharmacologically relevant dose and the previously established effective dose. OVCAR-5 cell clusters showed limited responses to resveratrol and its derivative.
Resveratrol has been shown to be capable of reducing cancer growth in previous studies [38–41]. However, these studies use very high doses of the compound, for example Dann et al  used 100 μM and Ji et al  used up to 200 μM. Furthermore, we have measured the effect of repeat doses over a long time period as we hypothesised that because of the morphology of the ovarian cancer aggregates a much longer exposure time would be required to observe any changes. In contrast, the majority of the studies done to date have been in monolayer cultures using high doses of resveratrol and measuring its effects over short time periods [42–44]. The concentrations of resveratrol and its derivative in our study did not decrease the total expression of PCNA. It may be possible that due to the cell aggregate morphology there are different metabolic cell populations within the aggregates; cells that are at the rim are fully exposed to nutrients and would divide faster than cells inside the aggregates. When these aggregates are exposed to resveratrol and acetyl-resveratrol, cell integrity at the rim may be compromised and that may allow nutrients to penetrate deeper inside the aggregate. As a consequence, this will trigger cells inside the aggregates to express PCNA . Therefore, although there are less cells overall in treated aggregates, PCNA may be expressed by cells further inside the smaller aggregates compared to the large control aggregates, thus, PCNA appears to be unchanged after treatment.
The pathogenesis of ovarian cancer is dependent on various molecules present in peritoneal fluid. VEGF is a key regulator of angiogenesis, a physiological process that is very important to cancer survival, which is associated with cell proliferation  and migration . VEGF is highly expressed by ovarian cancer and bystander cells and its concentration is associated with tumour aggression and a poor prognosis , as such it is implicated in ovarian cancer pathology. The current study measured the expression of VEGF after treatments with resveratrol and acetyl-resveratrol and found that the VEGF production from SKOV-3 cell aggregates was attenuated by both compounds. The decrease in VEGF secretion correlates with the time- and dose-dependent growth restriction of SKOV-3, this result is in accordance with previous monolayer studies [47–49]. The level of VEGF secretion by OVCAR-5 was, however, very low (on average 8-fold less than SKOV-3) and unaffected by the treatments. This difference between cell lines, although not exclusively studied before, was not totally unexpected. The cell lines were chosen as they have different receptors for adhesion  and have different morphology when grown as a monolayer or as 3D cell aggregates or clusters. SKOV-3 cells form large dense aggregates, whereas OVCAR-5 cells form small clusters. The distinct morphology of the cell lines in the 3D model may contribute to the activation of signalling molecules that associate with the transcriptional profile of VEGF.
Unexpectedly the secretion response of IL-8 is the reverse of VEGF. IL-8 is a cytokine that under normal conditions is involved in the inflammatory process, where it attracts and activates neutrophils at the site of infection , and is also a potent promoter of angiogenesis . Both of these processes are keys to cancer cell survival and metastasis. Furthermore, IL-8 has been shown to have these effects in ovarian cancer [36, 52]. Huang et al.  indicated that VEGF and IL-8 secretion are closely correlated and even potentially controlled by the same intracellular signalling pathway. Additional studies even suggest that IL-8 controls the expression of VEGF . However, the effect we elicited on IL-8 with resveratrol and acetyl-resveratrol is contrary to these suppositions. The increased secretion of IL-8 in response to resveratrol has been observed before in normal human keratinocytes . Potapovich et al.  first stimulated the cells with TNFα and then challenged them with 50 μM resveratrol and found that IL-8 secretion was upregulated. Considering all this evidence, we propose that resveratrol is suppressing one signalling pathway that controls VEGF expression whilst possibly up-regulating one that controls IL-8 expression. It is possible that the production of IL-8 in our study conditions may reflect a compensatory mechanism that the cancer cells are using to overcome the lack of VEGF.
In an effort to elucidate the molecules or mechanism targeted by resveratrol and acetyl-resveratrol, we measured the expression of proteins associated with the NF-κB signalling pathway. NF-κB is a family of 5 transcription factors in mammalian cells, RelA (p65), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2), which are able to form homo- and hetero-dimers . The NF-κB cascade involves this family as well as the upstream protein IκBα and toll-like receptors. Phosphorylation of NF-κB is implicated to be important to the transcription of IL-8 . The NF-κB family and signalling pathway promotes proliferation via regulation of genes such as cyclin D1, D3, has been linked to gastric , prostate  and breast malignancies  and has been studied extensively in lymphomas [57–59]. Our data shows that the NF-κB protein is attenuated by resveratrol and acetyl-resveratrol, and the expression of NF-κB observed in the nucleus in the SKOV-3 cell aggregates is markedly reduced. The phosphorylated form of the upstream protein IκBα was unaffected. We have also shown via NF-κB inhibition that the NF-κB protein is involved in the cell growth and secretion of VEGF of the cell lines. The inhibition of NF-κB was twice as effective as resveratrol in reducing cell metabolism, growth and VEGF secretion of the SKOV-3 aggregates suggesting that resveratrol may not be a single action compound, this is further supported by the opposing trends of IL-8 secretion between resveratrol and the NF-κB inhibitor. In OVCAR-5 cell clusters, NF-κB expression is very low and rarely visualized in the nucleus, whilst pNF-κB was below detectable levels, the cell growth was reduced by NF-κB inhibition, however, to a much lesser extent than the SKOV-3 aggregates. Taken together, these results may suggest that resveratrol and acetyl-resveratrol may attenuate the secretion of VEGF via the reduction of NF-κB protein level. It is possible that resveratrol and acetyl-resveratrol may be affecting the NF-κB protein at the transcriptional level. The present study is limited given the lack of growth effects of resveratrol and its derivative in normal ovarian epithelial cells.
Taken together, our results suggest that resveratrol and acetyl-resveratrol may exhibit anti-ovarian cancer properties through the inhibition of NF-κB. The polyphenols were able to reduce the growth of 3D ovarian cancer cells in a cell line-, concentration- and time-dependant manner. This growth restriction correlated with reduction and reduced nuclear localisation of the NF-κB protein. The reduction of NF-κB in turn correlated with the attenuation of VEGF secretion. Further studies of the anti-ovarian cancer growth activity of resveratrol and acetyl-resveratrol are warranted especially using in vivo animal models before clinical trials.
We thank Health Research Council (HRC), New Zealand for Alex Tino’s scholarship.
The authors declare that the work described has not been published previously.
This study was partly funded by Ovarian Cancer Research Foundation (OCRF), Melbourne, Australia.
Availability of data and materials
The data supporting the conclusion of this article is included within the article.
AT did experiments and prepared a manuscript. KC assisted with experiments and prepared a manuscript. PS assisted with manuscript preparation. AG assisted with experimental design and prepared manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.: GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. Available from: globocan iarc fr. 2014.
- Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107(6):1399–410.View ArticlePubMedGoogle Scholar
- Dembo AJ, Dave M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990;75(2):263–73.PubMedGoogle Scholar
- Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol. 2007;213(3):581–8.View ArticlePubMedGoogle Scholar
- Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials. 2010;31(32):8494–506.View ArticlePubMedGoogle Scholar
- Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor–positive human tumors. Blood J Am Soc Hematol. 2001;98(6):1904–13.Google Scholar
- Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi C, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol. 1996;149(1):293.PubMedPubMed CentralGoogle Scholar
- Nakanishi Y, Kodama J, Yoshinouchi M, Tokumo K, Kamimura S, Okuda H, et al. The expression of vascular endothelial growth factor and transforming growth factor-[beta] associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol. 1997;16(3):256–62.View ArticlePubMedGoogle Scholar
- Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6(4):373–8.View ArticlePubMedGoogle Scholar
- Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E, et al. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine. 2013;64(1):413–21.View ArticlePubMedGoogle Scholar
- Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam EE-d. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5):363–9.View ArticlePubMedGoogle Scholar
- Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002;277(27):24584–93.View ArticlePubMedGoogle Scholar
- Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, et al. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med. 2007;7(1):1.View ArticleGoogle Scholar
- Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–82.View ArticlePubMedGoogle Scholar
- De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini M, Di Fusco D, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34(27):3493–503.View ArticlePubMedGoogle Scholar
- Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Investig. 1997;100(12):2952.View ArticlePubMedPubMed CentralGoogle Scholar
- Xia J, Chen L, Jian W, Wang K-B, Yang Y, He W, et al. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J Transl Med. 2014;12(1):33.View ArticlePubMedPubMed CentralGoogle Scholar
- Gonzalez-Perez RR, Xu Y, Guo S, Watters A, Zhou W, Leibovich SJ. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFκB/HIF-1α activation. Cell Signal. 2010;22(9):1350–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Hirsch J, Johnson CL, Nelius T, Kennedy R, de Riese W, Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine. 2011;55(2):202–10.View ArticlePubMedGoogle Scholar
- Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G, Fuggetta MP. Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation. 2012;35(1):240–8.View ArticlePubMedGoogle Scholar
- Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50(3):179–87.PubMedGoogle Scholar
- Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci. 2011;1215(1):1–8.View ArticlePubMedGoogle Scholar
- Benitez DA, Hermoso MA, Pozo‐Guisado E, Fernández‐Salguero PM, Castellón EA. Regulation of cell survival by resveratrol involves inhibition of NFκB regulated gene expression in prostate cancer cells. Prostate. 2009;69(10):1045–54.View ArticlePubMedGoogle Scholar
- Karthikeyan S, Hoti SL, Prasad NR. Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small cell lung cancer cells. Biomed Pharmacother. 2015;70:274–82.View ArticlePubMedGoogle Scholar
- Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, et al. Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 2007;258(1):63–9.View ArticlePubMedGoogle Scholar
- Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, et al. Resveratrol has inhibitory effects on the hypoxia-induced inflammation and angiogenesis in human adipose tissue in vitro. Eur J Pharm Sci. 2013;49(2):251–7.View ArticlePubMedGoogle Scholar
- Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215(1):9–15.View ArticlePubMedGoogle Scholar
- Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.View ArticlePubMedGoogle Scholar
- Colin D, Gimazane A, Lizard G, Izard JC, Solary E, Latruffe N, et al. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro‐uracil sensitivity in human derived colon cancer cells. Int J Cancer. 2009;124(12):2780–8.View ArticlePubMedGoogle Scholar
- Liang L, Liu X, Wang Q, Cheng S, Zhang S, Zhang M. Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4′-tri-O-acetylresveratrol in rats. Phytomedicine. 2013;20(6):558–63.View ArticlePubMedGoogle Scholar
- Hogg SJ, Chitcholtan K, Hassan W, Sykes PH, Garrill A. Resveratrol, acetyl-resveratrol and polydatin exhibit anti-growth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstet Gynecol Int. 2015;2015:14.Google Scholar
- Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79(2):185–8.View ArticlePubMedGoogle Scholar
- Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One. 2013;8(2):e55309.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsukawa A, Yoshimura T, Maeda T, Ohkawara S, Takagi K, Yoshinaga M. Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. J Immuno. 1995;154(10):5418–25.Google Scholar
- Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, et al. Stress effects on FosB-and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010;285(46):35462–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(210):1471–2407.Google Scholar
- Dann JM, Sykes PH, Mason DR, Evans JJ. Regulation of vascular endothelial growth factor in endometrial tumour cells by resveratrol and EGCG. Gynecol Oncol. 2009;113(3):374–8.View ArticlePubMedGoogle Scholar
- Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One. 2013;8(11):e78700.View ArticlePubMedPubMed CentralGoogle Scholar
- Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002;8(3):893–903.PubMedGoogle Scholar
- Selvaraj S, Sun Y, Sukumaran P, Singh BB. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway. Mol Carcinog. 2015;55(5):818–31.View ArticlePubMedGoogle Scholar
- Gwak H, Kim S, Dhanasekaran DN, Song YS. Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells. Cancer Lett. 2016;371(2):347–53.View ArticlePubMedGoogle Scholar
- Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, et al. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst. 2012;8(4):1078–87.View ArticlePubMedGoogle Scholar
- Zhong L-X, Li H, Wu M-L, Liu X-Y, Zhong M-J, Chen X-Y, et al. Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells. J Ovarian Res. 2015;8(1):1.View ArticleGoogle Scholar
- Chitcholtan K, Sykes P, Evans J. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med. 2012;10:38.View ArticlePubMedPubMed CentralGoogle Scholar
- De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem. 2012;113(11):3363–70.View ArticlePubMedGoogle Scholar
- Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010;101(2):488–93.View ArticlePubMedGoogle Scholar
- Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem. 2011;286(15):13626–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis. 2010;13(4):305–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz PN. CD44 and B1 Integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol. 1999;154(5):1525–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–801.View ArticlePubMedGoogle Scholar
- Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W, et al. Regulatory effect of E2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol. 2005;2(5):365–72.PubMedGoogle Scholar
- Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60(19):5334–9.PubMedGoogle Scholar
- Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2009;284(10):6038–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Potapovich AI, Lulli D, Fidanza P, Kostyuk VA, De Luca C, Pastore S, et al. Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFkappaB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011;255(2):138–49.View ArticlePubMedGoogle Scholar
- Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-κB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol. 2008;28(11):3623–38.View ArticlePubMedPubMed CentralGoogle Scholar
- Hathcock KS, Padilla-Nash HM, Camps J, Shin D-M, Triner D, Shaffer AL, et al. ATM deficiency in absence of T cells promotes development of NF-kB-dependent murine B cell lymphomas that resemble human ABC DLBCL. Blood. 2015:blood-2015-06-654749.
- Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120(4):529–35.View ArticlePubMedGoogle Scholar
- Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18(49):6938–47.View ArticlePubMedGoogle Scholar